MDGL
NASDAQMadrigal Pharmaceuticals Inc.
Price$512.36-6.17 (-1.19%)
01:45 PM07:45 PM
News · 26 weeks61-10%
2026-03-012026-08-23
Mix3390d
- Other12(36%)
- Insider11(33%)
- SEC Filings6(18%)
- Analyst2(6%)
- Earnings1(3%)
- Leadership1(3%)
Latest news
25 items- INSIDERGeneral Counsel Kelley Shannon T sold $341,940 worth of shares (664 units at $514.97), decreasing direct ownership by 5% to 11,474 units (SEC Form 4) to cover taxes4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2026 to 13 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregat
- INSIDERDirector Reed John C was granted 647 shares (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERSEC Form 3 filed by new insider Reed John C3 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- SECMadrigal Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- PRMadrigal Appoints John C. Reed, M.D., Ph.D., to its Board of DirectorsCONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson ("J&J") and is a member of J&J’s Executive Committee, where he leads research and development across oncology, immunology, neuroscience and other areas of significant unmet medical need. Julian Baker, Chairman of the Board of Directors of Madrigal, stated, "I
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 1, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregat
- PRMadrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth ConferenceCONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, Aug. 11, 2026 at 12:00 P.M. EDT. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical ne
- ANALYSTMadrigal Pharmaceuticals upgraded by Wolfe Research with a new price targetWolfe Research upgraded Madrigal Pharmaceuticals from Peer Perform to Outperform and set a new price target of $605.00
- SECSEC Form 10-Q filed by Madrigal Pharmaceuticals Inc.10-Q - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- SECSEC Form 8-K filed by Madrigal Pharmaceuticals Inc.8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- PRMadrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate UpdatesSecond-quarter 2026 Rezdiffra® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling from 2Q25 reflecting continued strong physician adoption and high patient demandStrengthened IP portfolio with 3 new resmetirom patents, including F4c patent MGL-2086 (oral GLP-1) Phase 1 trial dosing initiated in June 2026 as part of Rezdiffra/MGL-2086 combination program in MASHReports cash, cash equivalents, restricted cash and marketable securities of $838.9 million as of June 30, 2026 Company to host conference call today, July 30, 2026, at 8 a.m. EDT CONSHOHOCKEN, Pa., July 30, 2026 (GLOBE N
- ANALYSTWells Fargo initiated coverage on Madrigal Pharmaceuticals with a new price targetWells Fargo initiated coverage of Madrigal Pharmaceuticals with a rating of Overweight and set a new price target of $685.00
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 15, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate
- INSIDERPresident and CEO Sibold William John converted options into 50,000 shares and sold $1,368,253 worth of shares (2,500 units at $547.30), increasing direct ownership by 29% to 209,329 units (SEC Form 4) to cover taxes4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- SECSEC Form 144 filed by Madrigal Pharmaceuticals Inc.144 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)
- PRMadrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. The webcast will be available approximately two ho
- PRMadrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP PortfolioReceived two new U.S. Rezdiffra® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well-compensated cirrhosis (F4c) CONSHOHOCKEN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the United States Patent and Trademark Office (USPTO) issued three new resmetirom patents. Bill Sibold, Chief Executive Officer of Madrigal, stated: "Building a robust patent estate is a core pillar of
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 1, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregat
- PRRibo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASHSUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. ((Madrigal, NASDAQ:MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies. This partnership fully underscores Ribo's and Madrigal's joint commitment to advan
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2026 to five new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregat
- INSIDERDirector Taub Rebecca was granted 454 shares, increasing direct ownership by 0.10% to 452,667 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERDirector Levy Richard S was granted 454 shares, increasing direct ownership by 2% to 22,469 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERDirector Fouse Jacqualyn A was granted 454 shares, increasing direct ownership by 41% to 1,551 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERDirector Daly James M was granted 454 shares, increasing direct ownership by 17% to 3,081 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
MDGL FAQ
7 questionsWhat does Madrigal Pharmaceuticals Inc. do?
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.Where does MDGL stock trade?
Madrigal Pharmaceuticals Inc. (MDGL) is listed on NASDAQ.What sector and industry is MDGL in?
Madrigal Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Madrigal Pharmaceuticals Inc. go public?
Madrigal Pharmaceuticals Inc. (MDGL) completed its IPO in 2007.What are analysts saying about MDGL?
Madrigal Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-08-04.What companies are similar to MDGL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MDGL side-by-side with any of them on Quantisnow.How can I track MDGL on Quantisnow?
Quantisnow aggregates Madrigal Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDGL to receive live email and push alerts on every new disclosure.